Craig Martin, founder and executive director of the nonprofit organization, said that more alternative models for commercializing gene therapies are likely to emerge in the future.1 According to the article, alternative models are proposed as a solution for sustaining access to expensive, single-use gene therapies.1 The article notes that the traditional business model - high, one-time prices paid by manufacturers - creates barriers to accessing and financing these drugs.[1] Alternative approaches mentioned in the article include risk-sharing models between payers and manufacturers and mechanisms tied to treatment outcomes.1 The article goes on to highlight the need for innovation in pricing and payment arrangements to ensure wider adoption of gene therapies in health care systems.1 The article also points out that implementing such models will require collaboration between manufacturers, health insurers, and regulators.1